Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
The offering will finance PolyPeptide Group’s acquisition and Bio Campus II expansion, with existing shareholders receiving most of the new shares.
- On Thursday, Samsung Biologics announced a rights offering to raise KRW 3 trillion to fund its long-term growth strategy across capacity, portfolio, and geographic expansion.
- Proceeds will support the acquisition of PolyPeptide Group for KRW 2.71 trillion and Bio Campus II expansion with KRW 290 billion, broadening the firm's portfolio into peptide-based therapeutics.
- Offering approximately 2,270,000 new shares at a 15% discount, President and CEO of Samsung Biologics John Rim said the raise "sets the stage for our next phase of growth."
- Existing shareholders receive priority on a pro-rata basis, with subscription scheduled for November 9–10 and new shares targeted for listing on November 30.
- To support next-generation therapies, the company is evaluating bringing Plants 6 through 8 online sequentially, aiming to reach 1,385,000 liters of global manufacturing capacity by 2032.
40 Articles
40 Articles
Samsung Biologics announced on the 28th a plan for a paid-in capital increase worth 3 trillion won. This is to fund the acquisition of Polypeptide Group, a Swiss contract development and manufacturing organization (CDMO) specializing in peptides. A portion of the proceeds will be used for the expansion of the Second Bio Campus in Songdo, Incheon. On this day, Samsung Biologics stated that it plans to issue 2.27 million new common shares at an es…
The Logan Banner
Samsung Biologics Announces KRW 3 Trillion Rights Offering to Fund Its Next-Phase Expansion
INCHEON, South Korea, Aug. 27, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today announced a rights offering to raise an expected aggregate amount of KRW 3 trillion to fund investments in the company's three-dimensional, long-term growth strategy across capacity, portfolio,…
(Seoul = Yonhap News) KOSPI-listed company Samsung Biologics [207940] plans a paid-in capital increase through a public offering of unsubscribed shares following a shareholder allocation to raise approximately 3 trillion won, including funds for acquiring securities of other companies...
Samsung Biologics announces 3 trillion won rights offering for expansion
INCHEON, South Korea, Aug. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today announced a rights offering to raise an expected aggregate amount of KRW 3 trillion to fund investments in the company's three-dimensional, long-term growth strategy across capacity, portfolio, and geographic expansion. The company plans to allocate approximately KRW 2.71 trillion of the offering proceeds toward the planned acquisition of PolyPeptide Gro…
[Digital Daily Reporter Kim Nam-gyu] Samsung Biologics plummeted more than 7% during trading on the 28th following the announcement of a 3 trillion won paid-in capital increase. Although the company emphasized that the move was a growth investment aimed at acquiring Polypeptide Group and expanding production facilities, the market reacted first to the possibility of shareholder value dilution resulting from the large-scale issuance of new shares…
Coverage Details
Bias Distribution
- 72% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
